|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAN |
Gene summary for RAN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAN | Gene ID | 5901 |
| Gene name | RAN, member RAS oncogene family | |
| Gene Alias | ARA24 | |
| Cytomap | 12q24.33 | |
| Gene Type | protein-coding | GO ID | GO:0000054 | UniProtAcc | B4DV51 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5901 | RAN | GSM4909282 | Human | Breast | IDC | 9.01e-03 | 2.32e-01 | -0.0288 |
| 5901 | RAN | GSM4909286 | Human | Breast | IDC | 4.25e-08 | -1.45e-01 | 0.1081 |
| 5901 | RAN | GSM4909288 | Human | Breast | IDC | 1.49e-04 | -6.56e-02 | 0.0988 |
| 5901 | RAN | GSM4909290 | Human | Breast | IDC | 9.90e-04 | 2.40e-01 | 0.2096 |
| 5901 | RAN | GSM4909291 | Human | Breast | IDC | 4.90e-02 | -4.21e-01 | 0.1753 |
| 5901 | RAN | GSM4909294 | Human | Breast | IDC | 3.22e-07 | 9.44e-03 | 0.2022 |
| 5901 | RAN | GSM4909296 | Human | Breast | IDC | 1.01e-15 | 4.80e-02 | 0.1524 |
| 5901 | RAN | GSM4909297 | Human | Breast | IDC | 7.28e-23 | -1.34e-01 | 0.1517 |
| 5901 | RAN | GSM4909298 | Human | Breast | IDC | 5.96e-03 | -2.11e-01 | 0.1551 |
| 5901 | RAN | GSM4909299 | Human | Breast | IDC | 4.27e-02 | -2.07e-01 | 0.035 |
| 5901 | RAN | GSM4909301 | Human | Breast | IDC | 8.91e-06 | -3.44e-01 | 0.1577 |
| 5901 | RAN | GSM4909302 | Human | Breast | IDC | 4.34e-03 | -3.79e-01 | 0.1545 |
| 5901 | RAN | GSM4909309 | Human | Breast | IDC | 2.21e-03 | -8.10e-02 | 0.0483 |
| 5901 | RAN | GSM4909311 | Human | Breast | IDC | 5.15e-49 | -4.78e-01 | 0.1534 |
| 5901 | RAN | GSM4909312 | Human | Breast | IDC | 7.30e-11 | -1.20e-01 | 0.1552 |
| 5901 | RAN | GSM4909313 | Human | Breast | IDC | 1.66e-06 | -3.83e-01 | 0.0391 |
| 5901 | RAN | GSM4909315 | Human | Breast | IDC | 3.82e-07 | 1.95e-01 | 0.21 |
| 5901 | RAN | GSM4909316 | Human | Breast | IDC | 2.48e-04 | 8.36e-02 | 0.21 |
| 5901 | RAN | GSM4909318 | Human | Breast | IDC | 2.74e-07 | 2.90e-01 | 0.2031 |
| 5901 | RAN | GSM4909319 | Human | Breast | IDC | 6.88e-66 | -4.29e-01 | 0.1563 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005117016 | Skin | cSCC | import into nucleus | 77/4864 | 159/18723 | 9.17e-10 | 3.58e-08 | 77 |
| GO:001820810 | Skin | cSCC | peptidyl-proline modification | 37/4864 | 58/18723 | 1.53e-09 | 5.82e-08 | 37 |
| GO:004325429 | Skin | cSCC | regulation of protein-containing complex assembly | 167/4864 | 428/18723 | 1.60e-09 | 5.97e-08 | 167 |
| GO:190018219 | Skin | cSCC | positive regulation of protein localization to nucleus | 49/4864 | 87/18723 | 1.84e-09 | 6.73e-08 | 49 |
| GO:006184215 | Skin | cSCC | microtubule organizing center localization | 25/4864 | 33/18723 | 3.13e-09 | 1.08e-07 | 25 |
| GO:0051222112 | Skin | cSCC | positive regulation of protein transport | 125/4864 | 303/18723 | 3.88e-09 | 1.32e-07 | 125 |
| GO:007265926 | Skin | cSCC | protein localization to plasma membrane | 118/4864 | 284/18723 | 6.43e-09 | 2.11e-07 | 118 |
| GO:199077824 | Skin | cSCC | protein localization to cell periphery | 134/4864 | 333/18723 | 7.09e-09 | 2.30e-07 | 134 |
| GO:005164214 | Skin | cSCC | centrosome localization | 24/4864 | 32/18723 | 9.21e-09 | 2.87e-07 | 24 |
| GO:000660615 | Skin | cSCC | protein import into nucleus | 73/4864 | 155/18723 | 1.13e-08 | 3.48e-07 | 73 |
| GO:000640513 | Skin | cSCC | RNA export from nucleus | 46/4864 | 84/18723 | 1.89e-08 | 5.56e-07 | 46 |
| GO:003150315 | Skin | cSCC | protein-containing complex localization | 95/4864 | 220/18723 | 2.00e-08 | 5.82e-07 | 95 |
| GO:0045185112 | Skin | cSCC | maintenance of protein location | 49/4864 | 94/18723 | 5.46e-08 | 1.40e-06 | 49 |
| GO:000726523 | Skin | cSCC | Ras protein signal transduction | 132/4864 | 337/18723 | 6.17e-08 | 1.57e-06 | 132 |
| GO:000661119 | Skin | cSCC | protein export from nucleus | 34/4864 | 57/18723 | 8.07e-08 | 1.96e-06 | 34 |
| GO:0032507111 | Skin | cSCC | maintenance of protein location in cell | 37/4864 | 65/18723 | 1.20e-07 | 2.79e-06 | 37 |
| GO:190290329 | Skin | cSCC | regulation of supramolecular fiber organization | 145/4864 | 383/18723 | 1.67e-07 | 3.71e-06 | 145 |
| GO:190437524 | Skin | cSCC | regulation of protein localization to cell periphery | 59/4864 | 125/18723 | 2.52e-07 | 5.28e-06 | 59 |
| GO:000005412 | Skin | cSCC | ribosomal subunit export from nucleus | 13/4864 | 14/18723 | 2.58e-07 | 5.33e-06 | 13 |
| GO:003375012 | Skin | cSCC | ribosome localization | 13/4864 | 14/18723 | 2.58e-07 | 5.33e-06 | 13 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
| hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
| hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
| hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
| hsa0516642 | Breast | DCIS | Human T-cell leukemia virus 1 infection | 41/846 | 222/8465 | 7.03e-05 | 6.88e-04 | 5.07e-04 | 41 |
| hsa0516652 | Breast | DCIS | Human T-cell leukemia virus 1 infection | 41/846 | 222/8465 | 7.03e-05 | 6.88e-04 | 5.07e-04 | 41 |
| hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
| hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
| hsa0516643 | Cervix | N_HPV | Human T-cell leukemia virus 1 infection | 22/349 | 222/8465 | 1.17e-04 | 1.18e-03 | 9.23e-04 | 22 |
| hsa0516653 | Cervix | N_HPV | Human T-cell leukemia virus 1 infection | 22/349 | 222/8465 | 1.17e-04 | 1.18e-03 | 9.23e-04 | 22 |
| hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
| hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
| hsa051662 | Colorectum | MSS | Human T-cell leukemia virus 1 infection | 68/1875 | 222/8465 | 1.84e-03 | 9.61e-03 | 5.89e-03 | 68 |
| hsa03250 | Colorectum | MSS | Viral life cycle - HIV-1 | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
| hsa051663 | Colorectum | MSS | Human T-cell leukemia virus 1 infection | 68/1875 | 222/8465 | 1.84e-03 | 9.61e-03 | 5.89e-03 | 68 |
| hsa032501 | Colorectum | MSS | Viral life cycle - HIV-1 | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
| hsa0516626 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
| hsa05166111 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
| hsa0516627 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
| hsa0516636 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAN | SNV | Missense_Mutation | novel | c.203N>A | p.Gly68Asp | p.G68D | P62826 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-AC-A8OS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RAN | insertion | Frame_Shift_Ins | novel | c.620_621insCCATGAAATTAACCAGTGTCTATTATATA | p.Ala208HisfsTer52 | p.A208Hfs*52 | P62826 | protein_coding | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| RAN | deletion | Frame_Shift_Del | c.329delN | p.Arg110GlnfsTer22 | p.R110Qfs*22 | P62826 | protein_coding | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD | |||
| RAN | SNV | Missense_Mutation | novel | c.640N>A | p.Asp214Asn | p.D214N | P62826 | protein_coding | deleterious(0.03) | benign(0.031) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| RAN | SNV | Missense_Mutation | c.628N>A | p.Pro210Thr | p.P210T | P62826 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAN | SNV | Missense_Mutation | rs201928609 | c.562N>T | p.Val188Phe | p.V188F | P62826 | protein_coding | tolerated(0.06) | benign(0) | TCGA-A6-5662-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD |
| RAN | SNV | Missense_Mutation | c.419N>A | p.Arg140Gln | p.R140Q | P62826 | protein_coding | tolerated(0.06) | benign(0.16) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RAN | SNV | Missense_Mutation | c.547N>A | p.Ala183Thr | p.A183T | P62826 | protein_coding | tolerated(0.16) | benign(0.019) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RAN | SNV | Missense_Mutation | c.542N>T | p.Ala181Val | p.A181V | P62826 | protein_coding | tolerated(0.06) | benign(0.019) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAN | SNV | Missense_Mutation | c.380N>C | p.Lys127Thr | p.K127T | P62826 | protein_coding | deleterious(0.03) | benign(0.271) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |